Sirolimus-Eluting Coronary Stents
- 6 June 2002
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 346 (23) , 1770-1771
- https://doi.org/10.1056/nejm200206063462302
Abstract
The story of sirolimus began in 1975 on Easter Island, in the South Pacific, a remote, enigmatic place known for the prominent stone statues that punctuate its landscape. An actinomycete, Streptomyces hygroscopicus, cultured from a sample of the island's soil, was found to produce through natural fermentation a novel macrolide antibiotic with potent antifungal, immunosuppressive, and antimitotic activities. The generic name of the resulting drug is sirolimus (see Figure); it is also known as rapamycin, after Rapa Nui, the name given to Easter Island by its inhabitants.Twenty-five years of intensive research led, in 1999, to the approval of sirolimus . . .Keywords
This publication has 0 references indexed in Scilit: